294 related articles for article (PubMed ID: 27400969)
1. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
[TBL] [Abstract][Full Text] [Related]
4. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Dubsky P; Brase JC; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Fisch K; Kronenwett R; Gnant M; Filipits M;
Br J Cancer; 2013 Dec; 109(12):2959-64. PubMed ID: 24157828
[TBL] [Abstract][Full Text] [Related]
5. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
6. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
[TBL] [Abstract][Full Text] [Related]
8. Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Buus R; Sestak I; Barron S; Loughman T; Fender B; Ruiz CL; Dynoodt P; Wang CA; O'Leary D; Gallagher WM; Dowsett M; Cuzick J
Clin Cancer Res; 2020 Feb; 26(3):623-631. PubMed ID: 31641007
[TBL] [Abstract][Full Text] [Related]
9. First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
Ettl J; Anders SI; Hapfelmeier A; Paepke S; Noske A; Weichert W; Klein E; Kiechle M
Arch Gynecol Obstet; 2020 Dec; 302(6):1461-1467. PubMed ID: 32902674
[TBL] [Abstract][Full Text] [Related]
10. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
Sestak I; Filipits M; Buus R; Rudas M; Balic M; Knauer M; Kronenwett R; Fitzal F; Cuzick J; Gnant M; Greil R; Dowsett M; Dubsky P
Clin Cancer Res; 2020 Sep; 26(17):4682-4687. PubMed ID: 32561662
[TBL] [Abstract][Full Text] [Related]
12. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
[TBL] [Abstract][Full Text] [Related]
13. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
Constantinidou A; Marcou Y; Toss MS; Simmons T; Bernhisel R; Hughes E; Probst B; Meek S; Kakouri E; Georgiou G; Zouvani I; Savvidou G; Kuhl V; Doedt J; Wagner S; Gutin A; Slavin TP; Lanchbury JS; Kronenwett R; Ellis IO; Rakha EA
Clin Cancer Res; 2022 Oct; 28(20):4435-4443. PubMed ID: 36043530
[TBL] [Abstract][Full Text] [Related]
14. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Dubsky P; Filipits M; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Kronenwett R; Brase JC; Gnant M;
Ann Oncol; 2013 Mar; 24(3):640-7. PubMed ID: 23035151
[TBL] [Abstract][Full Text] [Related]
15. Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Pece S; Sestak I; Montani F; Tillhon M; Maisonneuve P; Freddi S; Chu K; Colleoni M; Veronesi P; Disalvatore D; Viale G; Buus R; Cuzick J; Dowsett M; Di Fiore PP
Eur J Cancer; 2022 Mar; 164():52-61. PubMed ID: 35172273
[TBL] [Abstract][Full Text] [Related]
16. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Penault-Llorca F; Dalenc F; Chabaud S; Cottu P; Allouache D; Cameron D; Grenier J; Venat Bouvet L; Jegannathen A; Campone M; Debled M; Hardy-Bessard AC; Giacchetti S; Barthelemy P; Kaluzinski L; Mailliez A; Mouret-Reynier MA; Legouffe E; Cayre A; Martinez M; Delbaldo C; Mollon-Grange D; Macaskill EJ; Sephton M; Stefani L; Belgadi B; Winter M; Orfeuvre H; Lacroix-Triki M; Bonnefoi H; Bliss J; Canon JL; Lemonnier J; Andre F; Bachelot T
ESMO Open; 2024 May; 9(5):103443. PubMed ID: 38692082
[TBL] [Abstract][Full Text] [Related]
18. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract][Full Text] [Related]
19. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
20. Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
Jank P; Lindner JL; Lehmann A; Pfitzner BM; Blohmer JU; Horst D; Kronenwett R; Denkert C; Schmitt WD
Breast Cancer Res Treat; 2022 Jan; 191(2):327-333. PubMed ID: 34783927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
